

Appendix Table F40. Adverse effects after duloxetine vs. placebo, random effects model

Outcome	Reference	Active n/N	Control n/N	Relative risk (95% CI)	Weight, %	Absolute risk difference (95% CI)	Weight, %
Abnormal elevation in bilirubine	Millard, 2004 ³⁵⁰	1/227	9/231	0.11 (0.01; 0.89)	33.43	-0.04 (-0.06; -0.01)	40.86
Total bilirubin above ULN	Hurley, 2006 ³¹²	4/958	8/955	0.50 (0.15; 1.65)	66.57	-0.00 (-0.01; 0.00)	59.14
	Pooled	5/1185	17/1186	0.30 (0.08 1.20)	100	-0.02 (-0.05; 0.01)	100
	P value/I squared			0.22 33.00%		0.03 78.90%	
Abnormal elevation in alanine aminotransferase	Millard, 2004 ³⁵⁰	4/227	2/231	2.04 (0.38; 11.00)	3.38	0.01 (-0.01; 0.03)	56.46
ALT above ULN	Hurley, 2006 ³¹²	84/958	62/955	1.35 (0.99; 1.85)	96.62	0.02 (-0.00; 0.05)	43.54
	Pooled	88/1185	64/1186	1.37 (1.00; 1.87)	100	0.02 (-0.00; 0.03)	100
	P value/I squared			0.64 0.00%		0.39 0.00%	
Abnormal elevation in aspartate aminotransferase	Millard, 2004 ³⁵⁰	3/227	6/231	0.51 (0.13; 2.01)	28.62	-0.01 (-0.04; 0.01)	46.87
AST above ULN	Hurley, 2006 ³¹²	60/958	42/955	1.42 (0.97; 2.09)	71.38	0.02 (-0.00; 0.04)	53.13
	Pooled	63/1185	48/1186	1.06 (0.43; 2.64)	100	0.00 (-0.03; 0.04)	100
	P value/I squared			0.16 50.00%		0.06 72.40%	
Anorexia	Millard, 2004 ³⁵⁰	15/227	0/231	31.54 (1.90; 524.06)	17.1	0.07 (0.03; 0.10)	19.84
Anorexia	Hurley, 2006 ³¹²	37/958	2/955	18.44 (4.46; 76.3)	66.97	0.04 (0.02; 0.05)	59.74
Anorexia	Schagen van Leeuwen, 2008 ³⁷⁸	4/131	0/134	9.21 (0.5; 169.28)	15.93	0.03 (-0.00; 0.06)	20.42
	Pooled	56/1316	2/1320	18.10 (5.66; 57.85)	100	0.04 (0.02; 0.06)	100
	P value/I squared			0.84 0.00%		0.23 32.50%	
Anorgasmia	Hurley, 2006 ³¹²	13/958	0/955	26.92 (1.60; 452.12)	51.14	0.01 (0.01; 0.02)	81.44
Anorgasmia	Steers, 2007 ³⁸¹	5/153	0/153	11 (0.61; 197.22)	48.86	0.03 (0.00; 0.06)	18.56
	Pooled	18/1111	0/1108	17.38 (2.31; 130.72)	100	0.02 (0.00; 0.03)	100
	P value/I squared			0.66 0.00%		0.24 28.90%	
Anxiety	Hurley, 2006 ³¹²	18/958	7/955	2.56 (1.08; 6.11)	70.6	0.01 (0.00; 0.02)	61.05
Anxiety	Kinchen, 2005 ³³¹	9/224	2/227	4.56 (1.00; 20.87)	23.01	0.03 (0.00; 0.06)	20.6
Anxiety	Steers, 2007 ³⁸¹	5/153	0/153	11 (0.61; 197.22)	6.39	0.03 (0.00; 0.06)	18.35
	Pooled	32/1335	9/1335	3.21 (1.55; 6.66)	100	0.02 (0.01; 0.03)	100
	P value/I squared			0.56 0.00%		0.22 33.50%	

Appendix Table F40. Adverse effects after duloxetine vs. placebo, random effects model (continued)

Outcome	Reference	Active n/N	Control n/N	Relative risk (95% CI)	Weight, %	Absolute risk difference (95% CI)	Weight, %
Appetite decreased	Hurley, 2006 ³¹²	22/958	2/955	10.97 (2.59; 46.50)	34.81	0.02 (0.01; 0.03)	64.18
Appetite decreased	Kinchen, 2005 ³³¹	10/224	2/227	5.07 (1.12; 22.87)	32	0.04 (0.01; 0.07)	7.18
Appetite decreased	Lin, 2008 ³³⁹	4/60	1/61	4.07 (0.47; 35.34)	15.54	0.05 (-0.02; 0.12)	1.26
Appetite decreased	Bent, 2008 ²³⁴	6/300	0/288	12.48 (0.71; 220.56)	8.81	0.02 (0.00; 0.04)	21.58
Appetite decreased	Steers, 2007 ³⁸¹	6/153	0/153	13 (0.74 (23;.77)	8.84	0.04 (0.01; 0.07)	5.8
	Pooled	48/1695	5/1684	7.54 (3.21; 17.68)	100	0.02 (0.02; 0.03)	100
	P value/I squared			0.90 0.00%		0.64 0.00%	
Asthenia	Ghoniem, 2005 ²⁹³	6/104	0/97	12.13 (0.69; 212.55)	7.05	0.06 (0.10; 0.11)	4.14
Asthenia	Hurley, 2006 ³¹²	7/958	0/955	14.95 (0.86; 261.45)	7.05	0.01 (0.00; 0.01)	50.11
Asthenia	Lin, 2008 ³³⁹	3/60	1/61	3.05 (0.33; 28.51)	11.56	0.03 (-0.03; 0.10)	2.44
Asthenia	Cardozo, 2010 ²⁴⁹	27/1378	6/1380	4.51 (1.87; 10.88)	74.34	0.02 (0.01; 0.02)	43.31
	Pooled	43/2500	7/2493	5.03 (2.35; 10.75)	100	0.01 (0.00; 0.02)	100
	P value/I squared			0.76 0.00%		0.08 55.10%	
Constipation	Ghoniem, 2005 ²⁹³	15/104	3/97	4.66 (1.39; 15.61)	2.95	0.11 (0.04; 0.19)	2.98
Constipation	Millard, 2004 ³⁵⁰	29/227	4/231	7.38 (2.64; 20.65)	4.07	0.11 (0.06; 0.16)	6.62
Constipation	Hurley, 2006 ³¹²	105/958	22/955	4.76 (3.03; 7.47)	21.2	0.09 (0.07; 0.11)	15.57
Constipation	Kinchen, 2005 ³³¹	20/224	5/227	4.05 (1.55; 10.61)	4.65	0.07 (0.03; 0.11)	7.7
Constipation	van Kerrebroeck, 2004 ³⁹³	35/247	10/247	3.5 (1.77; 6.91)	9.31	0.10 (0.05; 0.15)	5.96
Constipation	Norton, 2002 ³⁵⁵	6/140	1/138	5.91 (0.72; 48.49)	0.97	0.04 (-0.00; 0.07)	9.29
Constipation	Castro-Diaz, 2007 ²⁵⁴	16/136	6/120	2.35 (0.95; 5.82)	5.25	0.07 (0.00; 0.13)	3.72
Constipation	Lin, 2008 ³³⁹	10/60	0/61	21.34 (1.28; 356.28)	0.54	0.17 (0.07; 0.26)	1.9
Constipation	Schagen van Leeuwen, 2008 ³⁷⁸	14/131	1/134	14.32 (1.91; 107.35)	1.06	0.10 (0.05; 0.15)	5.15
Constipation	Dmochowski, 2003 ²⁷⁹	33/344	7/339	4.65 (2.08; 10.36)	6.7	0.08 (0.04; 0.11)	9.9
Constipation	Bent, 2008 ²³⁴	25/300	12/288	2 (1.02; 3.91)	9.62	0.04 (0.00; 0.08)	8.54
Constipation	Steers, 2007 ³⁸¹	21/153	5/153	4.2 (1.63; 10.85)	4.78	0.11 (0.04; 0.17)	4.29
Constipation	Cardozo, 2010 ²⁴⁹	125/1378	31/1380	4.04 (2.75; 5.94)	28.89	0.07 (0.05; 0.09)	18.38
	Pooled	454/4402	107/4370	4.01 (3.26; 4.93)	100	0.08 (0.06; 0.09)	100
	P value/I squared			0.55 0.00%		0.10 35.10%	
Diarrhea	Hurley, 2006 ³¹²	49/958	26/955	1.88 (1.18; 3.00)	48.74	0.02 (0.01; 0.04)	27.08
Diarrhea	Kinchen, 2005 ³³¹	19/224	8/227	2.41 (1.08; 5.38)	16.4	0.05 (0.01; 0.09)	12.38
Diarrhea	Norton, 2002 ³⁵⁵	4/140	3/138	1.31 (0.30; 5.76)	4.86	0.01 (-0.03; 0.04)	15.23
Diarrhea	Castro-Diaz, 2007 ²⁵⁴	1/136	4/120	0.22 (0.03; 1.95)	2.24	-0.03 (-0.06; 0.01)	16

Appendix Table F40. Adverse effects after duloxetine vs. placebo, random effects model (continued)

Outcome	Reference	Active n/N	Control n/N	Relative risk (95% CI)	Weight, %	Absolute risk difference (95% CI)	Weight, %
Diarrhea	Dmochowski, 2003 ²⁷⁹	21/344	9/339	2.30 (1.07; 4.95)	18.1	0.03 (0.00; 0.07)	18.46
Diarrhea	Steers, 2007 ³⁸¹	10/153	5/153	2 (0.70; 5.72)	9.65	0.03 (-0.02; 0.08)	10.84
	Pooled	104/1955	55/1932	1.91 (1.38; 2.65)	100	0.02 (0; 0.04)	100
	P value/I squared			0.47 0.00%		0.07 50.70%	
Dizziness	Ghoniem, 2005 ²⁹³	19/104	5/97	3.54 (1.38; 9.12)	5.03	0.13 (0.05; 0.22)	3.2
Dizziness	Millard, 2004 ³⁵⁰	25/227	6/231	4.24 (1.77; 10.14)	5.92	0.08 (0.04; 0.13)	7.79
Dizziness	Cardozo, 2004 ²⁵¹	9/55	2/54	4.42 (1; 19.52)	2.04	0.13 (0.02; 0.24)	2.12
Dizziness	Hurley, 2006 ³¹²	91/958	25/955	3.63 (2.35; 5.60)	23.95	0.07 (0.05; 0.09)	13.78
Dizziness	Kinchen, 2005 ³³¹	30/224	8/227	3.8 (1.78; 8.11)	7.84	0.10 (0.05; 0.15)	6.9
Dizziness	van Kerrebroeck, 2004 ³⁹³	30/247	8/247	3.75 (1.75; 8.02)	7.8	0.09 (0.04; 0.14)	7.65
Dizziness	Norton, 2002 ³⁵⁵	7/140	2/138	3.45 (0.73; 16.32)	1.86	0.04 (-0.01; 0.08)	8.66
Dizziness	Castro-Diaz, 2007 ²⁵⁴	14/136	1/120	12.35 (1.65; 92.55)	1.11	0.10 (0.04; 0.15)	6.43
Dizziness	Lin, 2008 ³³⁹	8/60	6/61	1.36 (0.50; 3.67)	4.53	0.04 (-0.08; 0.15)	2
Dizziness	Schagen van Leeuwen, 2008 ³⁷⁸	12/131	6/134	2.05 (0.79; 5.29)	4.99	0.05 (-0.01; 0.11)	5.48
Dizziness	Dmochowski, 2003 ²⁷⁹	26/344	8/339	3.20 (1.47; 6.97)	7.43	0.05 (0.02; 0.08)	10.77
Dizziness	Bent, 2008 ²³⁴	29/300	7/288	3.98 (1.77; 8.94)	6.87	0.07 (0.03; 0.11)	9.41
Dizziness	Cardozo, 2010 ²⁴⁹	68/1378	23/1380	2.96 (1.86; 4.72)	20.64	0.03 (0.02; 0.05)	15.8
	Pooled	368/4304	107/4271	3.33 (2.69; 4.11)	100	0.07 (0.045; 0.08)	100
	P value/I squared			0.86 0.00%		0.01 56.20%	
Dry mouth	Ghoniem, 2005 ²⁹³	19/104	3/97	5.91 (1.81; 19.34)	6.36	0.15 (0.07; 0.23)	5.12
Dry mouth	Millard, 2004 ³⁵⁰	28/227	4/231	7.12 (2.54; 19.98)	7.39	0.11 (0.06; 0.15)	7.97
Dry mouth	Cardozo, 2004 ²⁵¹	12/55	0/54	24.55 (1.49; 404.63)	1.75	0.22 (0.11; 0.33)	3.53
Dry mouth	Kinchen, 2005 ³³¹	26/224	5/227	5.27 (2.06; 13.48)	8.09	0.09 (0.05; 0.14)	7.95
Dry mouth	van Kerrebroeck, 2004 ³⁹³	48/247	6/247	8 (3.49; 18.35)	9	0.17 (0.12; 0.22)	7.35
Dry mouth	Norton, 2002 ³⁵⁵	7/140	1/138	6.9 (0.86; 55.35)	2.89	0.04 (0.00; 0.08)	8.6
Dry mouth	Castro-Diaz, 2007 ²⁵⁴	22/136	5/120	3.88 (1.52; 9.93)	8.09	0.12 (0.05; 0.19)	5.85
Dry mouth	Lin, 2008 ³³⁹	10/60	2/61	5.08 (1.16; 22.24)	4.83	0.13 (0.03; 0.24)	3.87
Dry mouth	Schagen van Leeuwen, 2008 ³⁷⁸	26/131	2/134	13.30 (3.22; 54.90)	5.09	0.18 (0.11; 0.26)	5.86
Dry mouth	Dmochowski, 2003 ²⁷⁹	42/344	3/339	13.80 (4.32; 44.08)	6.51	0.11 (0.08; 0.15)	8.84

Appendix Table F40. Adverse effects after duloxetine vs. placebo, random effects model (continued)

Outcome	Reference	Active n/N	Control n/N	Relative risk (95% CI)	Weight, %	Absolute risk difference (95% CI)	Weight, %
Dry mouth	Bent, 2008 ²³⁴	36/300	8/288	4.32 (2.04; 9.14)	9.72	0.09 (0.05; 0.13)	8.37
Dry mouth	Steers, 2007 ³⁸¹	25/153	2/153	12.5 (3.01; 51.86)	5.07	0.15 (0.09; 0.21)	6.65
Dry mouth	Cardozo, 2010 ²⁴⁹	117/1378	47/1380	2.49 (1.79; 3.47)	13.56	0.05 (0.03; 0.07)	10.19
Dry mouth	Hurley, 2006 ³¹²	128/958	14/955	9.11 (5.29; 15.71)	11.65	0.12 (0.10; 0.14)	9.86
	Pooled	546/4457	102/4424	6.26 (4.22; 9.28)	100	0.12 (0.09; 0.14)	100
	P value/I squared			0.00 58.20%		0 78.60%	
Fatigue	Millard, 2004 ³⁵⁰	23/227	8/231	2.93 (1.34; 6.40)	6.04	0.07 (0.02; 0.11)	8.93
Fatigue	Cardozo, 2004 ²⁵¹	10/55	6/54	1.64 (0.64; 4.19)	4.2	0.07 (-0.06; 0.20)	2.52
Fatigue	Hurley, 2006 ³¹²	122/958	36/955	3.38 (2.36; 4.85)	28.49	0.09 (0.07; 0.11)	11.92
Fatigue	Kinchen, 2005 ³³¹	45/224	12/227	3.8 (2.07; 6.99)	9.98	0.15 (0.09; 0.21)	7.14
Fatigue	van Kerrebroeck, 2004 ³⁹³	34/247	11/247	3.09 (1.60; 5.96)	8.6	0.09 (0.04; 0.14)	8.36
Fatigue	Norton, 2002 ³⁵⁵	10/140	3/138	3.29 (0.92; 11.68)	2.3	0.05 (0.00; 0.10)	8.49
Fatigue	Lin, 2008 ³³⁹	5/60	0/61	11.18 (0.63; 197.86)	0.45	0.08 (0.01; 0.16)	5.6
Fatigue	Schagen van Leeuwen, 2008 ³⁷⁸	19/131	7/134	2.78 (1.21; 6.38)	5.35	0.09 (0.02; 0.160)	5.98
Fatigue	Dmochowski, 2003 ²⁷⁹	51/344	13/339	3.87 (2.14; 6.98)	10.64	0.11 (0.07; 0.15)	9.35
Fatigue	Bent, 2008 ²³⁴	20/300	8/288	2.4 (1.07; 5.36)	5.74	0.04 (0.01; 0.07)	10.59
Fatigue	Steers, 2007 ³⁸¹	16/153	3/153	5.33 (1.59; 17.93)	2.52	0.09 (0.03; 0.14)	7.96
Fatigue	Cardozo, 2010 ²⁴⁹	65/1378	21/1380	3.1 (1.91; 5.04)	15.68	0.03 (0.02; 0.05)	13.16
	Pooled	420/4217	128/4207	3.22 (2.66; 3.90)	100	0.08 (0.05; 0.10)	100
	P value/I squared			0.94 0.00%		0 73.70%	
Headache	Millard, 2004 ³⁵⁰	33/227	20/231	1.68 (0.99; 2.84)	9.44	0.06 (0; 0.12)	4.8
Headache	Cardozo, 2004 ²⁵¹	15/55	5/54	2.95 (1.15; 7.54)	2.94	0.18 (0.04; 0.32)	0.87
Headache	Hurley, 2006 ³¹²	93/958	63/955	1.47 (1.08; 2)	27.54	0.03 (0.01; 0.06)	21.9
Headache	Kinchen, 2005 ³³¹	28/224	14/227	2.03 (1.10; 3.75)	6.87	0.06 (0.01; 0.12)	5.69
Headache	van Kerrebroeck, 2004 ³⁹³	24/247	19/247	1.26 (0.71; 2.25)	7.84	0.02 (-0.03; 0.07)	6.51
Headache	Norton, 2002 ³⁵⁵	8/140	9/138	0.88 (0.35; 2.21)	3.05	-0.01 (-0.06; 0.05)	5.15
Headache	Castro-Diaz, 2007 ²⁵⁴	11/136	11/120	0.88 (0.40; 1.96)	4.07	-0.01 (-0.08; 0.06)	3.5
Headache	Dmochowski, 2003 ²⁷⁹	25/344	12/339	2.05 (1.05; 4.02)	5.75	0.04 (0.00; 0.07)	13.02
Headache	Steers, 2007 ³⁸¹	13/153	8/153	1.63 (0.69; 3.81)	3.58	0.03 (-0.02; 0.09)	5.11
Headache	Cardozo, 2010 ²⁴⁹	109/1378	64/1380	1.71 (1.26; 2.30)	28.93	0.03 (0.02; 0.05)	33.46
	Pooled	359/3862	225/3844	1.58 (1.35; 1.86)	100	0.03 (0.02; 0.05)	100

Appendix Table F40. Adverse effects after duloxetine vs. placebo, random effects model (continued)

Outcome	Reference	Active n/N	Control n/N	Relative risk (95% CI)	Weight, %	Absolute risk difference (95% CI)	Weight, %
	P value/I squared			0.57 0.00%		0.34 10.90%	
Hyperhidrosis	Lin, 2008 ³³⁹	5/60	0/61	11.18 (0.63; 197.86)	0.94	0.08 (0.01; 0.16)	3.1
Hyperhidrosis	Schagen van Leeuwen, 2008 ³⁷⁸	7/131	0/134	15.34 (0.89; 265.91)	0.95	0.05 (0.01; 0.09)	8.15
Hyperhidrosis	Cardozo, 2010 ²⁴⁹	45/1378	13/1380	3.47 (1.88; 6.40)	20.58	0.02 (0.01; 0.03)	22.23
Hyperhidrosis	Brunton, 2010 ²³⁹	189/10326	34/7496	4.04 (2.80; 5.81)	58.33	0.01 (0.01; 0.02)	25.17
Hyperhidrosis	Millard, 2004 ³⁵⁰	13/227	2/231	6.62 (1.51; 28.98)	3.54	0.05 (0.02; 0.08)	10.84
Hyperhidrosis	Kinchen, 2005 ³³¹	15/224	1/227	15.20 (2.03; 114.11)	1.9	0.06 (0.03; 0.10)	10.34
Hyperhidrosis	Hurley, 2006 ³¹²	43/958	8/955	5.36 (2.53; 11.34)	13.76	0.04 (0.02; 0.05)	20.17
	Pooled	317/13304	58/10484	4.34 (3.29; 5.73)	100	0.04 (0.02; 0.05)	100
	P value/I squared			0.69 0.00%		0 79.40%	
Insomnia	Ghoniem, 2005 ²⁹³	12/104	1/97	11.19 (1.48;84.47)	2.85	0.11 (0.04; 0.17)	7.07
Insomnia	Millard, 2004 ³⁵⁰	31/227	6/231	5.26 (2.24;12.36)	9.09	0.11 (0.06; 0.16)	8.3
Insomnia	Cardozo, 2004 ²⁵¹	7/55	3/54	2.29 (0.63; 8.40)	5.6	0.07 (-0.04; 0.18)	4.37
Insomnia	Hurley, 2006 ³¹²	121/958	18/955	6.70 (4.12; 10.91)	13.41	0.11 (0.09; 0.13)	10.24
Insomnia	Kinchen, 2005 ³³¹	33/224	13/227	2.57 (1.39; 4.76)	11.81	0.09 (0.04; 0.15)	7.8
Insomnia	van Kerrebroeck, 2004 ³⁹³	31/247	3/247	10.33 (3.20; 33.36)	6.41	0.11 (0.07; 0.16)	8.76
Insomnia	Norton, 2002 ³⁵⁵	7/140	1/138	6.9 (0.86; 55.35)	2.71	0.04 (0.00; 0.08)	9.13
Insomnia	Castro-Diaz, 2007 ²⁵⁴	14/136	6/120	2.06 (0.82;5.19)	8.41	0.05 (-0.01; 0.12)	7.1
Insomnia	Dmochowski, 2003 ²⁷⁹	49/344	8/339	6.04 (2.90; 12.55)	10.42	0.12 (0.08; 0.16)	9.01
Insomnia	Bent, 2008 ²³⁴	7/300	7/288	0.96 (0.34; 2.70)	7.44	-0.00 (-0.03; 0.02)	10.13
Insomnia	Steers, 2007 ³⁸¹	20/153	5/153	4 (1.54; 10.38)	8.14	0.10 (0.04; 0.16)	7.4
Insomnia	Cardozo, 2010 ²⁴⁹	63/1378	24/1380	2.63 (1.65; 4.18)	13.7	0.03 (0.02; 0.04)	10.69
	Pooled	395/4266	95/4229	3.76 (2.59; 5.47)	100	0.08 (0.05; 0.11)	100
	P value/I squared			0.01 55.20%		0 86.90%	
Nausea	Ghoniem, 2005 ²⁹³	40/104	5/97	7.46 (3.07; 18.13)	6.09	0.33 (0.23; 0.44)	5.49
Nausea	Millard, 2004 ³⁵⁰	57/227	9/231	6.45 (3.27; 12.71)	7.72	0.21 (0.15; 0.27)	7.51
Nausea	Cardozo, 2004 ²⁵¹	25/55	7/54	3.51 (1.66; 7.42)	7.13	0.33 (0.17; 0.48)	3.48
Nausea	Hurley, 2006 ³¹²	222/958	35/955	6.32 (4.48; 8.93)	10.74	0.20 (0.17; 0.22)	8.92
Nausea	Kinchen, 2005 ³³¹	70/224	13/227	5.46 (3.11; 9.58)	8.76	0.26 (0.19; 0.32)	7.21
Nausea	van Kerrebroeck, 2004 ³⁹³	69/247	16/247	4.31 (2.58; 7.21)	9.21	0.22 (0.15; 0.28)	7.41
Nausea	Norton, 2002 ³⁵⁵	13/140	2/138	6.41 (1.47; 27.87)	3.22	0.08 (0.03; 0.13)	7.98

Appendix Table F40. Adverse effects after duloxetine vs. placebo, random effects model (continued)

Outcome	Reference	Active n/N	Control n/N	Relative risk (95% CI)	Weight, %	Absolute risk difference (95% CI)	Weight, %
Nausea	Castro-Diaz, 2007 ²⁵⁴	40/136	7/120	5.04 (2.35; 10.83)	7.01	0.24 (0.15; 0.32)	6.23
Nausea	Lin, 2008 ³³⁹	9/60	0/61	19.31 (1.15; 324.56)	1.08	0.15 (0.06; 0.24)	5.93
Nausea	Schagen van Leeuwen, 2008 ³⁷⁸	10/131	4/134	2.56 (0.82; 7.95)	4.6	0.05 (-0.01; 0.10)	7.9
Nausea	Dmochowski, 2003 ²⁷⁹	78/344	7/339	10.98 (5.14; 23.45)	7.06	0.21 (0.16; 0.25)	8.23
Nausea	Bent, 2008 ²³⁴	54/300	13/288	3.99 (2.23; 7.15)	8.57	0.13 (0.09; 0.19)	8.09
Nausea	Steers, 2007 ³⁸¹	47/153	7/153	6.71 (3.13; 14.38)	7.03	0.26 (0.18; 0.34)	6.58
Nausea	Cardozo, 2010 ²⁴⁹	279/1378	113/1380	2.47 (2.01; 3.04)	11.78	0.12 (0.10; 0.15)	9.04
	Pooled	1013/4457	238/4424	5.02 (3.70; 6.82)	100	0.19 (0.15; 0.22)	100
	P value/I squared			0 70.40%		0 84.30%	
Sleep disorder	Schagen van Leeuwen, 2008 ³⁷⁸	4/131	1/134	4.09 (0.46; 36.12)	6.18	0.02 (-0.01; 0.06)	8.58
Somnolence	Ghoniem, 2005 ²⁹³	11/104	1/97	10.26 (1.35; 77.99)	6.84	0.10 (0.03; 0.16)	5.43
Somnolence	Millard, 2004 ³⁵⁰	19/227	0/231	39.68 (2.41; 653.35)	4.17	0.08 (0.05; 0.12)	8.13
Somnolence	Cardozo, 2004 ²⁵¹	7/55	1/54	6.87 (0.88; 54.00)	6.69	0.11 (0.01; 0.20)	3.25
Somnolence	Hurley, 2006 ³¹²	65/958	1/955	64.80 (9.01; 466.01)	7.12	0.07 (0.05; 0.08)	10.33
Somnolence	Kinchen, 2005 ³³¹	23/224	4/227	5.83 (2.05; 16.58)	14.22	0.09 (0.04; 0.13)	7.38
Somnolence	van Kerrebroeck, 2004 ³⁹³	10/247	0/247	21 (1.24; 356.41)	4.1	0.04 (0.02; 0.07)	9.4
Somnolence	Castro-Diaz, 2007 ²⁵⁴	15/136	2/120	6.62 (1.55; 28.35)	10.42	0.09 (0.04; 0.15)	5.89
Somnolence	Lin, 2008 ³³⁹	9/60	0/61	19.31 (1.15; 324.56)	4.12	0.15 (0.06; 0.24)	3.32
Somnolence	Dmochowski, 2003 ²⁷⁹	30/344	1/339	29.56 (4.06; 215.57)	7.05	0.08 (0.05; 0.12)	8.87
Somnolence	Bent, 2008 ²³⁴	8/300	1/288	7.68 (0.97; 61.02)	6.64	0.02 (0.00; 0.04)	10.03
Somnolence	Steers, 2007 ³⁸¹	6/153	0/153	13 (0.74; 228.77)	4.01	0.04 (0.01; 0.07)	8.57
Somnolence	Cardozo, 2010 ²⁴⁹	28/1378	12/1380	2.34 (1.19; 4.58)	18.45	0.01 (0.00; 0.02)	10.81
	Pooled	235/4317	24/4286	8.61 (4.58; 16.20)	100	0.06 (0.04; 0.08)	100
	P value/I squared			0.08 38.40%		0 85.20%	
Treatment associated adverse effects	Dmochowski, 2003 ²⁷⁹	255/344	170/339	1.48 (1.31; 1.68)	13.35	0.24 (0.17; 0.31)	13.9
Treatment associated adverse effects	Millard, 2004 ³⁵⁰	173/227	137/231	1.29 (1.13; 1.46)	12.63	0.169 0.085 0.253	11.46
Treatment associated adverse effects	van Kerrebroeck, 2004 ³⁹³	200/247	158/247	1.27 (1.13; 1.42)	14.93	0.17 (0.09; 0.25)	12.61

Appendix Table F40. Adverse effects after duloxetine vs. placebo, random effects model (continued)

Outcome	Reference	Active n/N	Control n/N	Relative risk (95% CI)	Weight, %	Absolute risk difference (95% CI)	Weight, %
Treatment associated adverse effects	Cardozo, 2004 ²⁵¹	51/55	39/54	1.28 (1.07; 1.54)	7.98	0.21 (0.07; 0.34)	5.77
Treatment associated adverse effects	Kinchen, 2005 ³³¹	198/224	159/227	1.26 (1.15; 1.39)	17.06	0.18 (0.11; 0.26)	13.44
Treatment associated adverse effects	Steers, 2007 ³⁸¹	121/153	85/153	1.42 (1.21; 1.68)	9.27	0.24 (0.13; 0.34)	9.01
Treatment associated adverse effects	Lin, 2008 ³³⁹	48/60	27/61	1.81 (1.33; 2.46)	3.29	0.36 (0.20; 0.52)	4.49
Treatment associated adverse effects	Schagen van Leeuwen, 2008 ³⁷⁸	58/131	49/134	1.21 (0.90; 1.63)	3.59	0.08 (-0.04; 0.20)	7.32
Treatment associated adverse effects	Cardozo, 2010 ²⁴⁹	666/1378	460/1380	1.45 (1.32; 1.59)	17.88	0.15 (0.11; 0.19)	21.99
	Pooled	1769/2819	1283/282 6	1.36 (1.28; 1.44)	100	0.19 (0.15; 0.22)	100
	P value/I squared			0.12 37.70%		0.07 44.60%	
Vomiting	Millard, 2004 ³⁵⁰	14/227	4/231	3.56 (1.19; 10.66)	7.65	0.04 (0.01; 0.08)	6.05
Vomiting	Cardozo, 2004 ²⁵¹	7/55	1/54	6.87 (0.88; 54.00)	2.16	0.11 (0.01; 0.20)	0.85
Vomiting	Hurley, 2006 ³¹²	46/958	15/955	3.06 (1.72; 5.44)	27.71	0.03 (0.02; 0.05)	29.24
Vomiting	Kinchen, 2005 ³³¹	19/224	8/227	2.41 (1.08; 5.38)	14.17	0.05 (0.01; 0.09)	4.02
Vomiting	van Kerrebroeck, 2004 ³⁹³	16/247	5/247	3.2 (1.19; 8.60)	9.4	0.05 (0.01; 0.08)	6.1
Vomiting	Steers, 2007 ³⁸¹	5/153	3/153	1.67 (0.41; 6.85)	4.6	0.01 (-0.02; 0.05)	5.98
Vomiting	Cardozo, 2010 ²⁴⁹	54/1378	19/1380	2.85 (1.70; 4.78)	34.31	0.03 (0.01; 0.04)	47.75
		161/3242	55/3247	2.9 (2.14; 3.93)	100	0.03 (0.02; 0.04)	100
				0.95 0.00%		0.40 2.90%	
Adverse effects	Bent, 2008 ²³⁴	5/300	5/288	0.96 (0.28; 3.28)	61.32	-0.00 (-0.02; 0.02)	57.85
	Steers, 2007 ³⁸¹	6/153	1/153	6 (0.73; 49.25)	38.68	0.03 (-0.00; 0.07)	42.15
	Pooled	11/453	6/441	1.95 (0.34; 11.22)	100	0.01 (-0.02; 0.05)	100
	P value/I squared			0.14 53.90%		0.10 63.90%	